On August 19, 2026, Merck (NYSE:MRK | MRK Price Prediction) and Moderna (NASDAQ:MRNA) announced positive topline Phase 3 results from INTerpath-001 for intismeran autogene, an individualized neoantigen therapy paired with Keytruda in resected melanoma. The trial beat Keytruda alone on recurrence-free survival, and no specific efficacy numbers have been released yet. Nothing is approved. Still, both partners needed this. Merck faces the Keytruda U.S. patent cliff in 2028; the franchise generated $31.641 billion in 2025 sales, according to Genetic Engineering and Biotechnology News. Its mRNA collaborator, Moderna, needs a success story outside COVID.
The key here is that every individualized dose requires sequencing a patient’s tumor and running a bespoke manufacturing batch. That drives demand for sequencing capacity and bioprocessing consumables on a per-patient basis. Here are five companies positioned to benefit if this therapy reaches the market.
BioNTech, the Rival That Rose Anyway
BioNTech (NASDAQ:BNTX) is developing autogene cevumeran with Genentech, with enrollment complete in adjuvant colorectal cancer and a readout expected in 2027. Shares jumped 21.6% over the past week on read-across. BioNTech itself pushed back on that logic, telling analysts “new antigen vaccines are not created equal.” Traders bought the modality anyway.
Illumina, the Sequencing Toll Booth
Illumina (NASDAQ:ILMN) supplies the NovaSeq X systems used to identify tumor neoantigens. Shares rose 15.6% on the week to $223.22. Clinical markets already represent about 65% of sequencing consumables revenue, and CEO Jacob Thaysen told investors “oncology continues to lead the pack.” It is a razor-and-blade model that benefits whichever vaccine wins.
Pacific Biosciences, the High-Beta Version
Pacific Biosciences (NASDAQ:PACB) offers long-read HiFi sequencing and rose 5.8% over the past week to $1.28. However, this is a micro-cap with a $419 million market cap and a beta of 2.318. A percentage move on a dollar stock is not the same risk profile as one on a large cap, and long-read sequencing has less direct exposure to neoantigen workflows today than short-read platforms.
Repligen, the Pure-Play Bioprocessing Pick
Repligen (NASDAQ:RGEN) sells filtration, chromatography, and process analytics used to manufacture biologics. Per-patient production is consumables-intensive. Q2 delivered $204 million of revenue with 13% organic growth, and CEO Olivier Loeillot said the pending BioLife acquisition “fast-tracks our cell therapy leadership.” Shares trade at $181.62.
Danaher, the Diversified Way to Own It
Danaher (NYSE:DHR) owns Cytiva and Pall, the deepest bioprocessing franchise in the group, plus Leica Biosystems in cancer diagnostics. Q2 bioprocessing orders grew mid-teens, and CEO Rainer Blair called the Life Sciences result “their strongest quarter in several years.” Danaher offers less upside torque than Repligen but more downside protection, and it does not need this specific therapy to succeed.
Counterweight and What to Watch
Leerink Partners analyst Daina Graybosch called the market reaction “overly optimistic,” warning that melanoma has the highest tumor mutational burden, so read-across is not automatic, and that per-patient manufacturing caps gross margin near 50% to 75% versus roughly 90% for monoclonal antibodies. That margin compression is exactly what shows up as revenue for the toolmakers. Even so, Leerink raised its 2032 intismeran forecast to $1.4 billion, while Morningstar now projects $16.8 billion by 2035.
Watch the actual efficacy numbers at the upcoming medical meeting and whether the result extends to lung, bladder, and renal cancers, where intismeran is already being evaluated across nine Phase 2 and Phase 3 studies. That is the falsifiable checkpoint.
Contact [email protected] for any questions or corrections.
Top Gaining Stocks
Top Losing Stocks